DEVELOPING TRANSFORMATIVE THERAPIES TO TREAT THE WHOLE EYE

Company Highlights

• NASDAQ: OCGN
• Strong global IP
• Diversified Portfolio with Three Waves of Technological Innovation

<table>
<thead>
<tr>
<th>Indication</th>
<th>Prevalence (US)</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>OCULAR SURFACE DISEASE (small molecule)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCU300 oGVHD</td>
<td>63,000</td>
<td>Orphan US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MODIFIER GENE THERAPY PLATFORM</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCU400 NRZET Mutation-Associated Retinal Degeneration</td>
<td>500-600</td>
<td>Orphan US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCU400 CEP290 Mutation-Associated Retinal Degeneration</td>
<td>2,500-3,000</td>
<td>Orphan US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCU410 RH0 Mutation-Associated Retinal Degeneration</td>
<td>10,400-12,700</td>
<td>Orphan US</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RETINAL DISEASES (novel biologic)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OCU200 Tumstatin Translens</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetic Macular Edema</td>
<td>745,000</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetic Retinopathy</td>
<td>7.7M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wet AMD</td>
<td>1.1M</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Quick Facts

Ticker: OCGN (NASDAQ)

Employees: 16 at 4/13/20

Cash & Investments: $7.6M at 12/31/19

Location: Malvern, PA

Shares Outstanding: 52.6M at 12/9/19

Strategic Partnership

Ocugen has entered into a strategic partnership with CanSino Biologics for the development of OCU400, Ocugen’s first product candidate in its modifier gene therapy platform.

Collaboration paves a path for Ocugen to advance OCU400 into the clinic with significantly reduced capital and resources.

Seasoned Management Team

Shankar Musunuri, PhD, MBA
Chairman, CEO & Co-Founder

Sanjay Subramanian, MBA
Chief Financial Officer

Dan Jorgensen, MD, MPH, MBA
Chief Medical Officer

Rasappa Arumugham, PhD
Chief Scientific Officer

Kelly Beck, MBA
VP, Investor Relations & Administration

Vijay Tammara, PhD
SVP, Regulatory & Quality
OCU300: oGVHD
Proprietary nanoemulsion of brimonidine tartrate for the treatment of ocular redness and ocular discomfort in patients with oGVHD

- Phase 3, 84-day Randomized, Double-Blinded, Placebo-Controlled Study
- 60 patients; 2:1 randomization
- Co-primary endpoints:
  - Symptom: Ocular discomfort based on Visual Analog Scale
  - Sign: Ocular redness based on Validated Bulbar Redness Score

OCU300: oGVHD Drug Delivery System
Increases brimonidine in lacrimal gland and improves overall efficacy of OCU300

OCU400: Wet AMD, DME, DR
Tumstatin-Transferrin Fusion Protein offering benefits beyond Anti-VEGF

- First company focused on macromolecule (fusion protein) to target integrins for ocular diseases
- Integrin-targeting based approaches are actively explored in a variety of disease treatments, such as cancer, autoimmune, angiogenic and fibrotic treatments
- Selectively works on active endothelial cells; targeting element enhances effective concentration

Key Targeted Milestones

**OCU300**
ocular GVHD
(Phase 3 small molecule)

- Mar 2020: Over 95% Planned Enrollment Achieved
- 2H2020: Topline Results Expected

**OCU400**
(RN2E3-AAV)
Retinal Degenerative Diseases
(gene therapy)

- 2020: Continue IND-Enabling Studies
- 2020: Initiated Tox Studies
- 2021: Target Phase 1/2a Clinical Trial

**OCU200**
Wet AMD, DME, DR
(novel biologic)

- 2020-2021: Continue IND-Enabling Studies
- 2022 Target Phase 1/2a Clinical Trial

For more information, please contact:
Kelly Beck, Vice President, Investor Relations
+1 484.328.4698 | kelly.beck@ocugen.com | www.ocugen.com

Forward Looking Statement: This document contains forward-looking statements that involve substantial risks and uncertainties. These statements, among other things, relate to our business strategy, future results of operations and financial position, prospective products, product approvals, research and development costs, timing and likelihood of success, estimated market size or growth, and plans and objectives of management for future operations. When used in this presentation, the words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements involve known and unknown risks, uncertainties and other factors, including those risks set forth in the our filings with the Securities and Exchange Commission, which are available at www.sec.gov, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information available to management as of the date hereof. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.